These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 32801898)

  • 21. Neoadjuvant chemotherapy
    Li Y; Ma FH; Xue LY; Tian YT
    World J Gastroenterol; 2020 Feb; 26(8):818-827. PubMed ID: 32148379
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical effects of Apatinib combined with DOS neoadjuvant chemotherapy regimen in neoadjuvant chemotherapy for LAGC.
    Zhou PZ; Gao L; Wu W; Hao YX
    Pak J Med Sci; 2021; 37(7):1890-1895. PubMed ID: 34912413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Clinical features and prognosis analysis of 21 gastric cancer patients with pathological complete response after neoadjuvant chemotherapy].
    Peng L; Yang W; Zhang Z; Liu H; Hua Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Oct; 20(10):1168-1173. PubMed ID: 29130233
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Novel computed tomography-based nomograms for the pretherapeutic prediction of response to neoadjuvant chemotherapy with S-1 and oxaliplatin with or without the addition of docetaxel in patients with advanced gastric cancer.
    Wu KS; Li KY; Gui Y; Li NP; Zhou HY; Zhang XM; Chen TW
    Quant Imaging Med Surg; 2024 Sep; 14(9):6711-6723. PubMed ID: 39281164
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Low-dose apatinib combined with camrelizumab and the SOX regimen in the neoadjuvant treatment of locally advanced gastric/gastroesophageal junction adenocarcinoma (SPACE-neo): a protocol for an open-label, single-arm, clinical trial.
    Pan L; Tian Y; Wang K; Tang J; Liu J; Zhang J; Wang M; Liu J; Xu H; Chen X
    J Gastrointest Oncol; 2022 Dec; 13(6):3300-3313. PubMed ID: 36636043
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Phase I study of neoadjuvant chemotherapy with S-1 and oxaliplatin for locally advanced gastric cancer (Neo G-SOX PI).
    Satake H; Miki A; Kondo M; Kotake T; Okita Y; Hatachi Y; Yasui H; Imai Y; Ichikawa C; Murotani K; Hashida H; Kobayashi H; Kotaka M; Kato T; Kaihara S; Tsuji A
    ESMO Open; 2017; 2(1):e000130. PubMed ID: 28761726
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Postoperative complications and their influence on the prognosis factors in gastric cancer patients receiving neoadjuvant treatment].
    Wang TB; Mao QK; Zhang XJ; Zhou H; Guo CG; Chen YT; Zhao DB
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Feb; 24(2):160-166. PubMed ID: 33508922
    [No Abstract]   [Full Text] [Related]  

  • 28. SOX combined with intraperitoneal perfusion of docetaxel compared with DOS regimen in the first-line therapy for advanced gastric cancer with malignant ascites: a prospective observation.
    Bin Y; Lan D; Bao W; Yang H; Zhou S; Huang F; Wang M; Peng Z
    Trials; 2022 Mar; 23(1):211. PubMed ID: 35279214
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Survival Benefit of Neoadjuvant Chemotherapy with S-1 Plus Docetaxel for Locally Advanced Gastric Cancer: A Propensity Score-Matched Analysis.
    Kano M; Hayano K; Hayashi H; Hanari N; Gunji H; Toyozumi T; Murakami K; Uesato M; Ota S; Matsubara H
    Ann Surg Oncol; 2019 Jun; 26(6):1805-1813. PubMed ID: 30977014
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Study protocol of a multicenter phase III randomized controlled trial investigating the efficiency of the combination of neoadjuvant chemotherapy (NAC) and neoadjuvant laparoscopic intraperitoneal hyperthermic chemotherapy (NLHIPEC) followed by R0 gastrectomy with intraoperative HIPEC for advanced gastric cancer (AGC): dragon II trial.
    Beeharry MK; Ni ZT; Yang ZY; Zheng YN; Feng RH; Liu WT; Yan C; Yao XX; Li C; Yan M; Zhu ZG
    BMC Cancer; 2020 Mar; 20(1):224. PubMed ID: 32183736
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical efficacy of neoadjuvant chemotherapy regimens FLEEOX vs. XELOX in patients with initially unresectable advanced gastric cancer: a propensity score analysis.
    Li Y; Chen J; He Q; Ji X; Wang X; Fan C; Li G
    Oncotarget; 2017 Oct; 8(49):86886-86896. PubMed ID: 29156843
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Survival Benefit of Perioperative Chemotherapy in Patients with Locally Advanced Gastric Cancer: a Propensity Score Matched Analysis.
    Eom BW; Kim S; Kim JY; Yoon HM; Kim MJ; Nam BH; Kim YW; Park YI; Park SR; Ryu KW
    J Gastric Cancer; 2018 Mar; 18(1):69-81. PubMed ID: 29629222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A phase I study of docetaxel/oxaliplatin/S-1 (DOS) combination neoadjuvant chemotherapy for patients with locally advanced adenocarcinoma of the esophagogastric junction.
    Hosoda K; Azuma M; Katada C; Ishido K; Niihara M; Ushiku H; Sakuraya M; Washio M; Wada T; Watanabe A; Harada H; Tanabe S; Koizumi W; Yamashita K; Hiki N
    Int J Clin Oncol; 2020 Jun; 25(6):1090-1097. PubMed ID: 32124094
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of oxaliplatin and tigio combination therapy in locally advanced gastric cancer.
    Wang T; Zhang LY
    World J Gastrointest Surg; 2024 Jun; 16(6):1709-1716. PubMed ID: 38983324
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Health-Related Quality of Life in Patients With Locally Advanced Gastric Cancer Undergoing Perioperative or Postoperative Adjuvant S-1 Plus Oxaliplatin With D2 Gastrectomy: A Propensity Score-Matched Cohort Study.
    Yu J; Wang Z; Li Z; Liu Y; Fan Y; Di J; Cui M; Xing J; Zhang C; Yang H; Yao Z; Zhang N; Chen L; Liu M; Xu K; Tan F; Gao P; Su X
    Front Oncol; 2022; 12():853337. PubMed ID: 35444949
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant chemotherapy with S-1 plus oxaliplatin improves survival of patients with gastric cancer after D2 gastrectomy: A multicenter propensity score-matched study.
    Ren DF; Zheng FC; Zhao JH; Shen GS; Ahmad R; Zhang SS; Zhang Y; Kan J; Dong L; Wang ZY; Zhao FX; Zhao JD
    World J Clin Cases; 2018 Sep; 6(10):373-383. PubMed ID: 30283800
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trial.
    Zhang X; Liang H; Li Z; Xue Y; Wang Y; Zhou Z; Yu J; Bu Z; Chen L; Du Y; Wang X; Wu A; Li G; Su X; Xiao G; Cui M; Wu D; Chen L; Wu X; Zhou Y; Zhang L; Dang C; He Y; Zhang Z; Sun Y; Li Y; Chen H; Bai Y; Qi C; Yu P; Zhu G; Suo J; Jia B; Li L; Huang C; Li F; Ye Y; Xu H; Wang X; Yuan Y; E JY; Ying X; Yao C; Shen L; Ji J;
    Lancet Oncol; 2021 Aug; 22(8):1081-1092. PubMed ID: 34252374
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prediction model of objective response after neoadjuvant chemotherapy in patients with locally advanced gastric cancer.
    Xu W; Fan Z; Wang L; He C; Ni Z; Hua Z; Zhu Z; Yang Z; Zheng Y; Feng R; Yan C; Li C; Yao X; Chen M; Yan M; Zhu Z; Liu W
    Am J Transl Res; 2021; 13(3):1568-1579. PubMed ID: 33841680
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgery for locally advanced gastric cancer in the era of neoadjuvant therapies: something new?
    Rosa F; Laterza V; Schena CA; Tondolo V; Strippoli A; Covino M; Pacini G; Quero G; Fiorillo C; DE Sio D; Tortora G; Alfieri S
    Minerva Surg; 2023 Oct; 78(5):481-489. PubMed ID: 37283508
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The Effect of Neoadjuvant Therapies for Patients with Locally Advanced Gastric Cancer: A Propensity Score Matching Study.
    Wang T; Chen Y; Zhao L; Zhou H; Wu C; Zhang X; Zhou A; Jin J; Zhao D
    J Cancer; 2021; 12(2):379-386. PubMed ID: 33391434
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.